Am J Transplant, Volume 17, Suppl 3 Archives - Page 44 of 181 - ATC Abstracts

2017 American Transplant Congress
A-Antigen (Ag)-Specific Tolerance Following A-Ag Administration to Infant Mice.
B. Motyka,¹ Y. Wang,¹ B. Lamarche,¹ I. Adam,¹ J. Pearcey,¹ K. Tao,¹ C. Cairo,² P. Cowan,³ L. West.¹
¹Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, Canada; ²Dept Chemistry, Alberta Glycomics Centre, University of Alberta, Edmonton, Canada; ³Immunology Research Centre, St Vincent's Hospital, University of Melbourne, Melbourne, Australia
Purpose: In contrast to adults, ABO-incompatible heart transplantation (ABOi HTx) can safely be performed in infants due to absent/low levels of anti-A/B antibodies (Ab). Tolerance…
2017 American Transplant Congress
Which Tr1 Is Better for Transplant Tolerance Induction: Comparing the Tr1 Generated by IL-27 or TGF-βplus IL-27.
G. Gu, H. Hang, Q. Xia.
Department of Hepatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
IL-10 producing T cells (Tr1) are important for the transplant tolerance induction. However, Tr1 can be induced in two methods: IL-27 or TGF-βplus IL-27. We…
2017 American Transplant Congress
Exosomes Containing IL35 Are Secreted by Donor-Specific Regulatory T Cells and Cause Linked-Suppression.
Y. Tomita,¹ W. Bracamonte-Baran,¹ E. Jankowska-Gan,¹ Q. Zhang,² D. Vignali,² W. Burlingham.¹
¹Surgery, Transplant Division, University of Wisconsin-Madison, Madison, WI; ²Immunology, University of Pittsburgh, Pittsburgh
Introduction: We previously reported that donor specific splenocytes transfusion (DST) plus anti-CD40L costimulatory blockade treatment causes allo-specific regulation approximately 5 weeks after the tolerization. The…
2017 American Transplant Congress
Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model.
J. Cwykiel, N. Filipek, E. Szilagyi, E. Tfaily, M. Siemionow.
Orthopaedics, University of Illinois at Chicago, Chicago, IL
Background: Cell therapies are a promising approach for tolerance induction in Vascularized Composite Allotransplantation (VCA). Thus, we have developed a new supportive therapy of ex…
2017 American Transplant Congress
Activation of Inflammation Amplifier in Kidney Graft and Urinary Biomarker for Chronic Rejection.
H. Higuchi,^1,2 D. Iwami,¹ K. Hotta,¹ N. Shinohara,¹ M. Murakami.²
¹Hokkaido University, Renal and Genitourinary Surgery, Sapporo, Hokkaido, Japan; ²Hokkaido University, Molecular Neuroimmunology, Institute of Genetic Medicine, Graduate School of Medicine, Sapporo, Hokkaido, Japan
[Introduction and Objective] Inflammation amplifier (IA), a local chemokine inducer in non-immune cells is induced by simultaneous activation of NFκB and STATs (IL-17, TNFα, and…
2017 American Transplant Congress
Protective Effect of New Delivery System of Nitric Oxide Releasing Nanofiber in Rat Model of Renal Ischemia-Reperfusion Injury.
J. Kim,¹ H. Ahn,² D. Kim,¹ S. Jung,¹ E. Park,¹ T. Lee,¹ C. Ihm,¹ S. Lee,¹ J. Moon,¹ Y. Kim,¹ K. Jeong.¹
¹Nephrology, Kyung Hee University Medical Center, Seoul, Korea; ²Surgery, Kyung Hee University Medical Center, Seoul, Korea
Objective: Renal ischemia-reperfusion injury (IRI) is very important in various clinical setting including kidney transplantation. Nitric oxide (NO) is well known for having various protective…
2017 American Transplant Congress
Split Liver Ex-situ Oxygenated Machine Perfusion: A Novel Approach to Organ Preservation and Treatment.
N. Karimian,¹ V. Huang,¹ S. Geerts,¹ S. Mert,¹ I. Beijert,² F. Fontan,¹ M. Aburawi,¹ R. Porte,² K. Uygun,¹ J. Markmann,¹ H. Yeh.¹
¹Division of Transplantation, Massachusetts General Hospital, Boston; ²Division of Transplantation, University Medical Center Groningen, Groningen, Netherlands
Ex-situ machine perfusion (MP) is a promising method to improve organ viability prior to transplantation and is being used in various clinical trials worldwide. However,…
2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
B. Burrell,¹ J. Bromberg,² C. Hartono,³ A. Posselt,⁴ A. Naji,⁵ D. Kaufman,⁶ R. Redfield III,⁶ S. Kanaparthi,¹ D. Ikle,⁷ K. Much,⁷ N. Bridges,⁸ L. Sun,¹ A. Priore,⁸ M. DesMarais,¹ K. Crisalli,⁹ S. Chandran,¹ J. Markmann.⁹
¹ITN, Bethesda/San Francisco; ²UMD, Baltimore; ³Rogosin, New York; ⁴UCSF, San Francisco; ⁵UPenn, Philadelphia; ⁶UWisconsin, Madison; ⁷Rho, Chapel Hill; ⁸NIAID/NIH, Bethesda; ⁹MGH, Boston
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…
2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
K. Unagami,¹ M. Okumi,² T. Hirai,² D. Toki,³ H. Shirakawa,⁴ T. Shimizu,² K. Omoto,⁵ M. Inui,³ H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan; ⁴Urology, Ohkubo Hospital, Tokyo, Japan; ⁵Transplant Surgery, Toda Chuo General Hospital, Toda, Japan
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…
2017 American Transplant Congress
Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients.
G. Chen, C. Wang, Z. Wu, C. Wang, J. Qiu, L. Chen.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Calcineurin inhibitor(CNI) nephrotoxicity is one of the major reasons for chronic allograft injury in live kidney transplantation from old donors to young recipients. Therefore…